Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Nanjing Medical University

Status and phase

Not yet enrolling

Phase 2

Conditions

Hormone Receptor-positive Advanced Breast Cancer

Treatments

Drug: chidamide，fulvestrant

Study type

Interventional

Funder types

Other

Identifiers

NCT05808582

CSIIT-C37

Details and patient eligibility

About

evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC

Full description

This trial is a single-arm study. Designed to evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+/HER2- advanced breast cancer that has failed previous CDK4/6 inhibitor combined with aromatase inhibitor therapy

Enrollment

60 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years, female.
Both postmenopausal and premenopausal for hormone receptor positive patients, but premenopausal patients need to be given concomitant ovarian function suppression (OFS) therapy (criteria for menopause: "Judgment Criteria for Menopause after Adjuvant Therapy and Consensus on Clinical Application of Aromatase Inhibitors for Premenopausal Female Breast Cancer Patients in China").
Patients with HR-positive (ER-positive, PR-positive or negative) and HER2-negative breast cancer confirmed by histopathology, defined as follows.
Pre-enrollment disease status of non-surgically resectable locally advanced or metastatic breast cancer.
At least one extracranial measurable lesion as defined by RECIST V1.1 criteria or bone metastases alone.
Progress after previous treatment with CDK4/6 inhibitor combined with any aromatase inhibitor (after previous treatment with CDK4/6 inhibitor combined with aromatase inhibitor, you can enter the study directly or re-enter the group after chemotherapy); ; The total number of previous rescue treatments is ≤3; Previously received rescue chemotherapy ≤1 line; Time interval from the last treatment: (a) If the last treatment is endocrine therapy, it needs ≥2 weeks; (b) If the last treatment is chemotherapy, it needs ≥4 weeks;
ECOG PS score: 0-1.
Organ function meets the requirement.
expected survival ≥ 3 months.
Subjects of childbearing potential need to have a negative pregnancy test within 7 days prior to initiation of treatment and must use an appropriate method of contraception during treatment and for three months after completion of treatment.
Patients are fully informed and voluntarily sign an informed consent form.

Exclusion criteria

Prior treatment with any HDAC inhibitor or fulvestrant.
known hypersensitivity to the drug components of this trial.
have inflammatory breast cancer at the time of screening
clinical evidence or history of central nervous system metastases (CS) and/or carcinomatous meningitis, soft meningeal disease
inability or unwillingness to swallow medications or receive intramuscular injections
have gastrointestinal insufficiency or gastrointestinal disease that can significantly interfere with the absorption of study drug (e.g., uncontrolled ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
History of immunodeficiency, including testing positive for HIV, or having other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
other malignancies (except cured basal cell carcinoma of the skin, cervical carcinoma in situ and thyroid cancer) within the previous 5 years or concurrently
having undergone a major surgical operation or significant trauma within 4 weeks prior to initiation of treatment, or where the patient is expected to undergo major surgical treatment
Inability to understand or follow study guidelines and requirements.
Those who are judged by the investigator to be unsuitable for participation in this study.